Literature DB >> 31433223

Hydropulsion as Palliative, Long-Term, Last-Resort Treatment of Nasal Carcinoma in a Dog and a Cat.

Tom Bienes1, Elisabeth Robin1, Kevin Le Boedec1.   

Abstract

An 8 yr old spayed female domestic shorthair and an 8 yr old neutered male Polish Lowland sheepdog were evaluated for a 3 wk history of sneezing and a 5 day history of left epistaxis, respectively. In both cases, computed tomography revealed a voluminous nasal mass, which was later histologically identified as carcinoma, without cribriform plate involvement. Nasal hydropulsion was performed in both animals in sternal recumbency under general anesthesia. A Poole suction tip was inserted into the orad esophageal opening and adequacy of the endotracheal tube cuff inflation was checked. Sterile saline was forcefully infused into the obstructed nasal cavity to dislodge the tumor. Both patients had temporary resolution of clinical signs. Nasal hydropulsion was repeated as a palliative last-resort treatment at each clinical relapse (four times in both animals over ≥1 yr), allowing long-term survival. Minor complications included a self-limiting retrobulbar and oropharyngeal swelling in the cat and self-limiting epistaxis in both animals. Although this technique is not intended to represent an equivalent alternative to radiation or surgical therapies, nasal hydropulsion may represent an appropriate palliative, last-resort treatment in case of obstructive nasal tumors in dogs and cats, when radiation therapy or surgery is not affordable, available, or desired.

Entities:  

Mesh:

Year:  2019        PMID: 31433223     DOI: 10.5326/JAAHA-MS-6901

Source DB:  PubMed          Journal:  J Am Anim Hosp Assoc        ISSN: 0587-2871            Impact factor:   1.023


  1 in total

1.  Retrospective evaluation of intranasal carcinomas in cats treated with external-beam radiotherapy: 42 cases.

Authors:  Hiroto Yoshikawa; Tracy L Gieger; Corey F Saba; Kirsha Fredrickson; Lyndsay Kubicek; Siobhan Haney; David Ruslander; Krista L Kelsey; Margaret C McEntee; Michael W Nolan
Journal:  J Vet Intern Med       Date:  2021-03-03       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.